Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

BACKGROUND: ENCORE1 demonstrated non-inferiority of daily efavirenz 400 mg (EFV400) versus 600 mg (EFV600) to 96 weeks in treatment-naïve, HIV-infected adults but concerns regarding lower EFV400 concentrations remained. Therefore, relationships between EFV pharmacokinetics (PK) and key genetic polym...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickinson, Laura, Amin, Janaki, Else, Laura, Boffito, Marta, Egan, Deirdre, Owen, Andrew, Khoo, Saye, Back, David, Orrell, Catherine, Clarke, Amanda, Losso, Marcelo, Phanuphak, Praphan, Carey, Dianne, Cooper, David A., Emery, Sean, Puls, Rebekah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916189/
https://www.ncbi.nlm.nih.gov/pubmed/26715213
http://dx.doi.org/10.1007/s40262-015-0360-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916189/
https://www.ncbi.nlm.nih.gov/pubmed/26715213
http://dx.doi.org/10.1007/s40262-015-0360-5

Ejemplares similares